Psilocybin’s neuroplastic potential reveals Alzheimer’s systemic gaps; single dose sparks dialogue in advanced case
Original framing: “Woman with Alzheimer's starts conversing again after taking psilocybin” — New Scientist
The suppression of psychedelics in the 20th century—rooted in Nixon’s War on Drugs and the CIA’s MK-Ultra experiments—created a 50-year gap in research, delaying understanding of neuroplasticity. Alzheimer’s research has been dominated by the amyloid hypothesis, despite its repeated failures, due to pharmaceutical industry incentives and the NIH’s funding priorities. Historical parallels exist in the marginalization of lithium for bipolar disorder until Western psychiatry ‘rediscovered’ it in the 1940s.
The case of the woman regaining speech after psilocybin is not merely a neurochemical anomaly but a symptom of deeper systemic failures: the pharmaceutical industry’s stranglehold on Alzheimer’s research, the erasure of Indigenous epistemologies, and the global neglect of holistic care models.
Western medicine’s late-stage fascination with psychedelics mirrors its historical pattern of co-opting indigenous innovations only when profitable, as seen with aspirin (derived from willow bark) or quinine (from cinchona bark). Yet the Mazatec, who have used teonanácatl for millennia to heal ‘forgotten words,’ offer a blueprint for reintegrating psychedelics into communal rituals that address cognitive decline as a spiritual and social rupture, not just a biochemical glitch. The real breakthrough lies not in isolating psilocybin’s active compound but in restoring the mycelial networks—of knowledge, ecology, and care—that Western science has systematically severed. To move forward, we must dismantle the colonial legacies that shape both medicine and memory, replacing them with systems where healing is co-created by patients, healers, and the earth itself.